Literature DB >> 26498671

Life-threatening ACE inhibitor-induced angio-oedema successfully treated with icatibant: a bradykinin receptor antagonist.

Sarah Ostenfeld1, Anette Bygum2, Eva Rye Rasmussen3.   

Abstract

We present a case of a 75-year-old woman treated with an ACE inhibitor, who presented with angio-oedema of the tongue and had difficulty speaking. No symptoms of anaphylaxis or urticaria were present. The patient was treated intravenously with antihistamine and glucocorticoid in combination with adrenaline inhalations. After 6 h in the hospital the swelling progressed, and the patient was admitted to the intensive care unit and treated with one injection of icatibant-a bradykinin receptor antagonist. The patient reported subjective relief after 20-30 min and the swelling resolved within 2 h. Although the angio-oedema was potentially life threatening, the patient avoided intubation and mechanical ventilation. ACE inhibitor-induced angio-oedema is most likely caused by an accumulation of bradykinin and substance P. Consequently, a bradykinin receptor antagonist is the rational treatment of choice instead of antiallergic medications, which have no proven efficacy in this condition. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26498671      PMCID: PMC4620216          DOI: 10.1136/bcr-2015-212891

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

1.  Incidence and characteristics of angioedema associated with enalapril.

Authors:  John B Kostis; Harold J Kim; James Rusnak; Thomas Casale; Allen Kaplan; Jonathan Corren; Elliott Levy
Journal:  Arch Intern Med       Date:  2005-07-25

2.  A randomized trial of icatibant in ACE-inhibitor-induced angioedema.

Authors:  Murat Baş; Jens Greve; Klaus Stelter; Miriam Havel; Ulrich Strassen; Nicole Rotter; Johannes Veit; Beate Schossow; Alexander Hapfelmeier; Victoria Kehl; Georg Kojda; Thomas K Hoffmann
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

3.  Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors.

Authors:  Mauro Gallitelli; Michele Alzetta
Journal:  Am J Emerg Med       Date:  2011-11-17       Impact factor: 2.469

4.  ACE-inhibitor induced angio-oedema treated with complement C1-inhibitor concentrate.

Authors:  Eva Rye Rasmussen; Anette Bygum
Journal:  BMJ Case Rep       Date:  2013-10-04

5.  Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department.

Authors:  Aleena Banerji; Sunday Clark; Michelle Blanda; Frank LoVecchio; Brian Snyder; Carlos A Camargo
Journal:  Ann Allergy Asthma Immunol       Date:  2008-04       Impact factor: 6.347

6.  Angiotensin-converting enzyme inhibitor-induced angioedema in a community hospital emergency department.

Authors:  Hazel M Bluestein; Todd A Hoover; Aleena Suryadevara Banerji; Carlos A Camargo; Avner Reshef; Paul Herscu
Journal:  Ann Allergy Asthma Immunol       Date:  2009-12       Impact factor: 6.347

7.  Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors.

Authors:  Donald R Miller; Susan A Oliveria; Dan R Berlowitz; Benjamin G Fincke; Paul Stang; David E Lillienfeld
Journal:  Hypertension       Date:  2008-04-14       Impact factor: 10.190

Review 8.  Nonallergic angioedema: role of bradykinin.

Authors:  M Bas; V Adams; T Suvorava; T Niehues; T K Hoffmann; G Kojda
Journal:  Allergy       Date:  2007-08       Impact factor: 13.146

9.  Life-threatening ACE inhibitor-induced angioedema after eleven years on lisinopril.

Authors:  Johanna L Norman; Whitney L Holmes; William A Bell; Shannon W Finks
Journal:  J Pharm Pract       Date:  2012-11-25

10.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

View more
  3 in total

Review 1.  [The ulm emergency algorithm for the acute treatment of drug-induced, bradykinin-mediated angioedema].

Authors:  J Hahn; B Bock; C-M Muth; A Pfaue; D Friedrich; T K Hoffmann; J Greve
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-09-19       Impact factor: 0.840

2.  The Influence of ACE Inhibition on C1-Inhibitor: A Biomarker for ACE Inhibitor-Induced Angioedema?

Authors:  Janina Hahn; Melanie Nordmann-Kleiner; Christoph Bönner; Georg Kojda; Thomas K Hoffmann; Jens Greve
Journal:  Biomed Hub       Date:  2019-05-07

Review 3.  How the Innate Immune System of the Blood Contributes to Systemic Pathology in COVID-19-Induced ARDS and Provides Potential Targets for Treatment.

Authors:  Bo Nilsson; Barbro Persson; Oskar Eriksson; Karin Fromell; Michael Hultström; Robert Frithiof; Miklos Lipcsey; Markus Huber-Lang; Kristina N Ekdahl
Journal:  Front Immunol       Date:  2022-03-08       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.